XML 93 R52.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Significant Agreements - Other (Details) - USD ($)
$ in Thousands
1 Months Ended 12 Months Ended
Dec. 31, 2019
May 31, 2014
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Dec. 31, 2004
Collaborative Arrangements and Non-collaborative Arrangement Transactions            
Research and development     $ 153,953 $ 103,902 $ 89,726  
License Agreement with a Non-profit Institution | Non-collaborative Arrangement Transactions            
Collaborative Arrangements and Non-collaborative Arrangement Transactions            
Research and development     3,700 100 100  
License Agreement With Antibody Technology Company            
Collaborative Arrangements and Non-collaborative Arrangement Transactions            
Research and development     2,100 $ 100 $ 1,600  
License Agreement With Fulcrum Therapeutics            
Collaborative Arrangements and Non-collaborative Arrangement Transactions            
Research and development     $ 10,000      
Minimum | License Agreement with a Non-profit Institution | Non-collaborative Arrangement Transactions            
Collaborative Arrangements and Non-collaborative Arrangement Transactions            
Milestone fees payable as percentage of research and U.S. development progress and sublicensing revenue           10.00%
Royalty payable as percentage of net sales           1.00%
Maximum | License Agreement with a Non-profit Institution | Non-collaborative Arrangement Transactions            
Collaborative Arrangements and Non-collaborative Arrangement Transactions            
Milestone fees payable as percentage of research and U.S. development progress and sublicensing revenue           25.00%
Royalty payable as percentage of net sales           3.50%
Development Milestones | Sotatercept | Maximum | Non-collaborative Arrangement Transactions            
Collaborative Arrangements and Non-collaborative Arrangement Transactions            
Total potential milestone payments           $ 2,000
Development Milestones | REBLOZYL Agreement | Maximum | Non-collaborative Arrangement Transactions            
Collaborative Arrangements and Non-collaborative Arrangement Transactions            
Total potential milestone payments           $ 700
Additional Research Fees | License Agreement With Antibody Technology Company            
Collaborative Arrangements and Non-collaborative Arrangement Transactions            
Collaborative arrangement amount paid and expensed   $ 300        
Additional Research Fees | License Agreement With Fulcrum Therapeutics            
Collaborative Arrangements and Non-collaborative Arrangement Transactions            
Collaborative arrangement amount paid and expensed $ 10,000          
Additional Research Fees | Maximum | License Agreement With Fulcrum Therapeutics            
Collaborative Arrangements and Non-collaborative Arrangement Transactions            
Total potential milestone payments 143,500          
Research, Development and Commercial Milestone Payments | Maximum | License Agreement With Fulcrum Therapeutics            
Collaborative Arrangements and Non-collaborative Arrangement Transactions            
Total potential milestone payments $ 295,000